Recently I published the list Billionaire Ken Griffin’s 10 mid-cap stock picks have huge upside down potential. In this article, we will introduce Neurocrine Biosciences, Inc. Let’s take a look where (NASDAQ: NBIX) will face other MidCap stock picks from billionaire Ken Griffin.
Ken Griffin, founder of CitadelHe is a controversial figure in the investment industry, but he is an influential figure. Ken Griffin tasted early successes during his college days during his trading, so it’s safe to say he’s never looked back since. Despite a big set-off during the 2008 financial crisis, he used his skills and determination to make a comeback where many others simply shut down their funds and moved.
The billionaire investor now manages approximately $65 billion worth of assets with his funds. Due to its size and track record of success, Ken Griffin’s stock moves often reach the news, with investors continuing in close proximity. We decided to do the same thing.
To come up with a list of billionaire Ken Griffin’s 10 mid-cap stock picks, we looked into his latest 13F Holdings and among his key holdings, only stocks with a market capitalization of between $10 billion and $40 billion were considered. We then looked at Wall Street average analyst price targets and ranked the stocks according to the likelihood of a stock’s rise.
Why are hedge funds interested in the stocks they accumulate? The reason is simple. Our research shows that mimic the top stock picks of the best hedge funds can outperform the market. Quarterly Newsletter’s strategy was to select 14 small and large caps per quarter, returning 373.4% since May 2014, surpassing the benchmark by 218 percentage points (For more information, please see here).
Medical experts discussing treatment options for patients with neurological disorders.
Possibility of inventory rise: 45.88%
Citadel Investment Group shares: $346,451,879
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) acts as a developer, discoverer and marketer of neuroendocrine, neuropsychiatry and neuropathic drugs. Its major product candidates include Ingrezza, Efmody Capsules, Orilissa Tablets, Oriahnn Capsules, Alkindi and Crenessity.
The company has been upgraded by RBC Capital Markets from sector performance, highlighting the recent market slump as an attractive purchasing opportunity. However, the price target was adjusted from $138 to $137 by RBC analyst Brian Abraham, and short-term fluctuations were expected due to long-term uncertainty surrounding the latest quarterly revenue and Medicare drug prices consultations.
